# Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

> **NCT03526887** · PHASE2 · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 73 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03526887
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-15
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-03-09
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526887, "Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03526887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*